Skip to content

Impact of CRISP on Self-Efficacy, Loneliness, and Depression

Effects of an Educational Socialization Program Designed to Improve Self-Efficacy and Subsequent Effects on Decreasing Loneliness and Depression Among People With Multiple Sclerosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02030197
Acronym
CRISP
Enrollment
118
Registered
2014-01-08
Start date
2014-02-28
Completion date
2014-12-31
Last updated
2014-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The purpose of this study is to examine the effects of an innovative program, entitled CRISP (Community Integration for Socially Isolated Patients), on improving self-efficacy and assessing whether improved self-efficacy helps to reduce depression and loneliness of people with MS.

Detailed description

Whether CRISP increases self-efficacy while decreasing loneliness and depression

Interventions

BEHAVIORALCRISP Program

Educational program to improve self-efficacy, loneliness and depression

OTHERControl Group

no treatment

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 18 to 65 years old. * Must have a definitive diagnosis of MS by a physician. * Must understand English at 6th grade level since the CRISP program requires participants to comprehend the educational information presented in English. * Agree to participate in 12 group sessions over 12 weeks; * Must have the ability to complete questionnaires in English since the outcome measures used for the study are in English. * Must be able to commute to the site destinations

Exclusion criteria

* Have an actively psychotic Axis I disorder. * Have a significant Axis II disorder of borderline personality disorder or schizoid personality disorder. * Have a diagnosis of another neurological condition aside from MS. * Inability to comply with study requirements/visits.

Design outcomes

Primary

MeasureTime frameDescription
Multiple Sclerosis Self-Efficacy Scale (MSSS)Change from Baseline to week 12The Multiple Sclerosis Self-Efficacy Scale (MSSS) is designed to measure self-efficacy in people diagnosed with MS. The MSSS incorporates aspects of social interaction and themes related to beliefs of control over future events, which is based on Bandura's definition of self-efficacy (Rigby et al., 2003). The MSSS is a 14 item, six-point Likert scale and participants are asked to rate their level of agreement or disagreement for each item on the scale ranging from 'strongly disagree' (1) to 'strongly agree' (6). Examples of questions include sometimes I feel embarrassed in public places or I have as much independence as I need. Scores can range from 14 (low self-efficacy) to 84 (high self-efficacy).

Secondary

MeasureTime frameDescription
UCLA Revised Loneliness ScaleChange from Baseline to week 12The UCLA Revised Loneliness Scale was developed to assess subjective feelings of loneliness and is widely used in loneliness research. The scale consists of 20 questions about loneliness asking participants to rate each question from 1 (never) to 4 (always), higher scores indicating greater degrees of loneliness.
Chicago Multiscale Depression Inventory (CMDI)Change from Baseline to week 12The Chicago Multiscale Depression Inventory will be used to assess symptoms of depression. The CMDI is a 50-item self-report measure that includes three subscales representing different types of depression symptoms: vegetative, mood, and evaluative. Each item on the scale consists of a single word or brief phrase describing feelings or experiences and participants rate each item on a Likert scale from 1 (not at all) to 5 (extremely).
Performance Scales (PS)Change from Baseline to week 12The Performance Scales (PS) is a self-reported measure of MS disease status assessing mobility, hand function, vision, fatigue, cognitive symptoms, bladder/bowel, sensory symptoms, spasticity, pain, depression, and tremor/coordination. Each scale of the PS (with the exception of the mobility scale) is a 6 item ordinal scale and participants are asked to describe their functioning in each area as compared to before they developed MS. Scores range from normal (0) to total disability in specified area (5) with higher scores indicating greater perceived disability. The mobility scale has a range from normal (0) to total gait disability or bedridden (6) and asks participants to choose the category that describes their walking ability in the past four weeks.
Community Integration Questionnaire (CIQ)Change from Baseline to week 12The Community Integration Questionnaire (CIQ) was developed to assess community integration after an injury with questions about home integration, social integration and productive activities. The CIQ is a 15 item self-report measure. The basis for scoring is by the frequency of performing specific activities and providing subtotals for each category of community integration as well as an overall score.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026